CoChat

Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates

Open access
Astvad, K.M.T., Hare, R.K., Arendrup, M.C. · 2017 · Clinical Microbiology and Infection
Cited by 48

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective The in vitro activity of isavuconazole was determined for 1677 Candida and 958 Aspergillus isolates from 2012 to 2014 with voriconazole as comparator. Methods Aspergillus isolates were screened for resistance using azole-agar. Aspergillus isolates that screened positive and all Candida isolates underwent EUCAST broth microdilution testing. Isolates were categorized as wild-type (wt) or non-wt, adopting EUCAST epidemiological cut-off values (ECOFFs) (where available) or wt upper limits (wtULs; two two-fold dilutions above the MIC 50 ). The CYP51A gene was sequenced for non-wt Aspergillus fumigatus isolates. Itraconazole and posaconazole MICs were determined for selected Aspergillus isolates with isavuconazole MIC ≥2 mg/L. Results Isavuconazole MIC 50 (range) (mg/L) against Candida species were: Candida albicans : ≤0.03 (≤0.03 to >4), Candida dubliniensis : ≤0.03 (≤0.03), Candida glabrata : ≤0.03 (≤0.03–4), Candida krusei : 0.06 (≤0.03–0.5), Candida parapsilosis : ≤0.03 (≤0.03–0.06), Candida tropicalis : ≤0.03 (≤0.03 to >4), Saccharomyces cerevisiae (anamorph: Candida robusta ): ≤0.03 (≤0.03–0.5). Non-wt isavuconazole/voriconazole MICs were found for C. albicans : 0.8/1.0%, C. dubliniensis : 0/1.8%, C. glabrata : 14.9/9.5%, C. krusei : 2.7/1.4%, C. parapsilosis : 1.7/1.8%, C. tropicalis : 14.3/19.1% and S. cerevisiae : 10.0/0%. Isavuconazole MIC 50 (range) (mg/L) against Aspergillus species were: A. fumigatus : 1 (≤0.125 to >16), Aspergillus niger : 2 (1–8), Aspergillus terreus : 1 (0.25–8), Aspergillus flavus : 1 (0.5–2), Aspergillus nidulans : ≤0.125 (≤0.125–0.25). Non-wt isavuconazole/voriconazole MICs were found for 13.7/15.2% A. fumigatus , 4.9/0% A. niger and 48.2/22.2% A. terreus . Conclusion Isavuconazole displayed broad in vitro activity, similar to that of voriconazole. Up to 15% of C. glabrata , C. tropicalis and A. fumigatus isolates were non-wt, reflecting increased resistance at a reference centre and technical issues. Significant CYP51A alterations were reliably detected applying the isavuconazole breakpoint.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmi.2017.03.023

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 48

Metadata

Authors
Astvad, K. M. T., Hare, R. K., & Arendrup, M. C.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2017-11
Volume
23
Issue
11
Pages
882-887
ISSN
1198-743X (ISSN-L)
OpenAlex
W2598411000
Cited by
48
References
5
FWCI
5.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. https://app.cochat.ai/papers/10.1016/j.cmi.2017.03.023
The paper
Astvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2017). Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2017.03.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.